Lkit Therapeutics: Exploiting Synethtic Lethality to Target p53 Mutant Cancers Using First-In-Class Potent and Selective Small Molecule Inhibitors of Lipid Kinases PI5P4Kα/β.
Yale Innovation Summit - Day 1
05/18/2021
Lkit Therapeutics: Exploiting Synethtic Lethality to Target p53 Mutant Cancers Using First-In-Class Potent and Selective Small Molecule Inhibitors of Lipid Kinases PI5P4Kα/β.
